AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $18.56 million. The enterprise value is $10.97 million.
Market Cap | 18.56M |
Enterprise Value | 10.97M |
Important Dates
The last earnings date was Thursday, May 16, 2024, before market open.
Earnings Date | May 16, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 51.28 million shares outstanding. The number of shares has increased by 2.19% in one year.
Shares Outstanding | 51.28M |
Shares Change (YoY) | +2.19% |
Shares Change (QoQ) | +1.16% |
Owned by Insiders (%) | 8.93% |
Owned by Institutions (%) | 7.98% |
Float | 46.71M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 96.19 |
Forward PS | n/a |
PB Ratio | 3.85 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 56.85 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.69.
Current Ratio | 1.15 |
Quick Ratio | n/a |
Debt / Equity | 0.69 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -431.19 |
Financial Efficiency
Return on equity (ROE) is -183.60% and return on invested capital (ROIC) is -407.47%.
Return on Equity (ROE) | -183.60% |
Return on Assets (ROA) | -128.30% |
Return on Capital (ROIC) | -407.47% |
Revenue Per Employee | $7,423 |
Profits Per Employee | -$1.20M |
Employee Count | 26 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.93% in the last 52 weeks. The beta is -0.11, so AIM ImmunoTech's price volatility has been lower than the market average.
Beta (1Y) | -0.11 |
52-Week Price Change | -21.93% |
50-Day Moving Average | 0.44 |
200-Day Moving Average | 0.47 |
Relative Strength Index (RSI) | 39.57 |
Average Volume (30 Days) | 247,344 |
Short Selling Information
The latest short interest is 433,194, so 0.84% of the outstanding shares have been sold short.
Short Interest | 433,194 |
Short Previous Month | 477,176 |
Short % of Shares Out | 0.84% |
Short % of Float | 0.93% |
Short Ratio (days to cover) | 2.49 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $193,000 and -$31.12 million in losses. Loss per share was -$0.64.
Revenue | 193,000 |
Gross Profit | 143,000 |
Operating Income | -33.32M |
Pretax Income | -31.12M |
Net Income | -31.12M |
EBITDA | -30.58M |
EBIT | -31.05M |
Loss Per Share | -$0.64 |
Balance Sheet
The company has $10.94 million in cash and $3.35 million in debt, giving a net cash position of $7.59 million or $0.15 per share.
Cash & Cash Equivalents | 10.94M |
Total Debt | 3.35M |
Net Cash | 7.59M |
Net Cash Per Share | $0.15 |
Equity / Book Value | 4.83M |
Book Value Per Share | 0.09 |
Working Capital | 1.43M |
Cash Flow
In the last 12 months, operating cash flow was -$22.40 million and capital expenditures -$32,000, giving a free cash flow of -$22.43 million.
Operating Cash Flow | -22.40M |
Capital Expenditures | -32,000 |
Free Cash Flow | -22.43M |
FCF Per Share | -$0.45 |
Margins
Gross margin is 74.09%, with operating and profit margins of -17,261.66% and -16,123.32%.
Gross Margin | 74.09% |
Operating Margin | -17,261.66% |
Pretax Margin | -16,123.32% |
Profit Margin | -16,123.32% |
EBITDA Margin | -15,843.01% |
EBIT Margin | -16,086.01% |
FCF Margin | -11,623.83% |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.19% |
Shareholder Yield | -2.19% |
Earnings Yield | -167.63% |
FCF Yield | -120.85% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | 202.96% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 11, 2019. It was a reverse split with a ratio of 1:44.
Last Split Date | Jun 11, 2019 |
Split Type | Reverse |
Split Ratio | 1:44 |
Scores
AIM ImmunoTech has an Altman Z-Score of -41.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -41.15 |
Piotroski F-Score | 3 |